Precision treatment significantly refines therapy outcomes for patients with HR+/HER2- breast cancer, enhancing effectiveness.
Real-world data from a clinical cohort of patients indicates notable treatment response after multiple prior therapies.
Analyzed treatments under a precision approach for patients in a metastatic setting, confirming improved patient management.
Findings support the need for tailored treatment strategies rather than traditional one-size-fits-all approaches.
Abstract
Treatment and response of a real-world clinical cohort of patients with advanced HR+/HER2- breast cancer who have undergone at least three prior lines of therapy in the metastatic setting